Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Medtronic plc
MDT
NYSE·Healthcare·Medical - Devices·Mkt cap $101.4B
$83.19
▲ +5.04%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$73.31 - $106.33
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 10.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Comprehensive medical device portfolio
- Global market presence
- Advanced technological innovation
- Strong research and development capabilities
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Aging global population
Value
Attractively priced below Medical Devices peer average
Momentum
Weak
-8.6% over 3m
Quality
Excellent
Excellent business quality
Dividend
Solid
3.60% yield
Smart-money signal
Who's buying MDT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 18, 2026
JUN 3, 2026
Reported EPS of $1.55 vs $1.54 consensus (+0.7% surprise). Revenue of $9.8B vs $9.6B expected (+1.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+0.7%
Next: Aug 18, 2026
Revenue trend · last 8Q
—
—
—
+3%
+4%
+8%
+7%
+9%
Q4 24
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
Q3 26
$8.6B
$7.9B
$8.4B
$8.3B
$8.9B
$8.6B
$9.0B
$9.0B
Margins · last 8Q
Gross
64.9%
Operating
19.7%
Profit
12.7%
Wall Street consensus
16 analysts · 56% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
56%
Hold
44%
Sell
0%
Median Price Target
$97.50
▲ +17.2% vs $83.19
Latest: Goldman Sachs · Jun 5, 2026
5 analysts covering